Spark Biomedical has received a $500,000 Clinical Research Award from the Trauma Research and Combat Casualty Care Collaborative (TRC4) to support a pilot clinical trial evaluating transcutaneous auricular neurostimulation (tAN) for chronic subdural hematoma (cSDH).
The study will be led by Dr. Alex Valadka at UT Southwestern Medical Center, with collaboration from investigators at UT Southwestern and University of Texas Medical Branch.
Chronic subdural hematoma:
Current treatment options include:
These interventions are invasive and carry risks of recurrence, complications, and procedural morbidity.
A non-invasive therapy would represent a paradigm shift.
The trial will use Spark’s Sparrow Link™ wearable neurostimulation system.
Preclinical and prior clinical research suggests tAN may influence:
These mechanisms are directly relevant to cSDH progression and recurrence.
Participants will self-administer daily 30-minute sessions for one month.
Primary:
Secondary:
Biomarkers:
Although small in size, the study is positioned as first-in-kind for non-invasive neuromodulation in cSDH.
If successful, tAN could:
This would extend neuromodulation beyond traditional indications like depression, epilepsy, and pain into acute/subacute neurosurgical disease.
Spark Biomedical positions itself within the bioelectronic medicine field — leveraging neural circuit modulation to treat systemic disease processes.
Key differentiators:
Federal funding support from agencies including NIH and the Department of Defense strengthens credibility in trauma-related indications.
Despite mechanistic plausibility:
Regulatory pathways for neuromodulation in neurotrauma may also require robust imaging and surgical outcome data.
Spark Biomedical’s TRC4-funded trial represents:
If positive, this study could position tAN as a novel adjunct or alternative to surgery in chronic subdural hematoma, and further validate bioelectronic medicine as a therapeutic modality beyond chronic neurological disorders.